Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intetumumab + Docetaxel in mCRPC
NCT00537381Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2007
- Primary completion
- Nov 2009
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 10
01
Overview
A Phase 2 trial of intetumumab in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Janssen Pharmaceutical. Started May 2007; status: completed.
02
Drugs
intetumumab
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT00537381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00537381.